This article has been updated to include Illumina's recorded gain on the sale.

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today said that it has coordinated the acquisition of Illumina's 13.5 percent stake in the company on behalf of certain shareholders.

The unnamed investors acquired Illumina's shares for £56.4 million ($90.7 million), and Illumina said in a regulatory filing Friday that it has recorded a $55.2 million gain from the sale of its stake in Oxford Nanopore.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.